Comments
Shares of Glenmark Pharmaceuticals were down by Rs 17.45 on the BSE after the company said it has lost its appeal to invalidate Abbott Laboratories' Tarka (trandolapril/verapamil hydrochloride) patent in a US court.
The company said that the Court of Appeals for the Federal Circuit, USA, had affirmed the district court's decision on April 22 with regard to Glenmark's marketing of a generic equivalent of Tarka. Glenmark said it was "disappointed with the decision'' and was considering its options.
The shares were trading at Rs 558.95, a loss of Rs 17.45, on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.